Gyre Therapeutics, Inc. Payments of Financing Costs
Gyre Therapeutics, Inc. (GYRE) reported Payments of Financing Costs of $1.49 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-08-07
- Gyre Therapeutics, Inc. payments of financing costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. payments of financing costs for the quarter ending 2025-09-30 was -$315.00K, a 730.00% decline year-over-year.
- Gyre Therapeutics, Inc. payments of financing costs for the quarter ending 2025-06-30 was $1.68M.
- Gyre Therapeutics, Inc. payments of financing costs for the quarter ending 2025-03-31 was $121.00K.
- Gyre Therapeutics, Inc. payments of financing costs for fiscal 2025 was $1.49M, a 177.43% increase from fiscal 2024.
- Gyre Therapeutics, Inc. payments of financing costs for fiscal 2024 was $536.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$315.00K derived: sum of 2 quarters · filed 2026-03-13 | $1.37M derived: sum of 3 quarters · filed 2026-08-07 | $1.49M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$315.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.37M derived: sum of 2 quarters · filed 2026-08-07 | $1.49M 10-Q · filed 2025-11-07 | $1.85M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.80M 10-Q · filed 2026-08-07 | $2.17M derived: sum of 3 quarters · filed 2026-08-07 | $2.22M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $121.00K 10-Q · filed 2026-05-08 | $488.00K derived: sum of 2 quarters · filed 2026-05-08 | $538.00K derived: sum of 3 quarters · filed 2026-05-08 | |
| 2024-12-31 | $367.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $417.00K derived: sum of 2 quarters · filed 2026-03-13 | $536.00K 10-K · filed 2026-03-13 | |
| 2024-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $169.00K 10-Q · filed 2025-11-07 | ||
| 2024-06-30 | $119.00K 10-Q · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |